secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001213900-24-096025
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed announces 1-for-20 reverse share split to regain Nasdaq $1 bid compliance
-------------------------------------------------------------------------------

- Consolidation ratio 1:20 reduces shares from ~14.36M to ~718k on a non-diluted basis.
- Effective with Nasdaq on Nov 14, 2024; adjusted trading begins Nov 15, symbol INM unchanged.
- No fractional shares issued; fractions under 0.5 cancelled, otherwise rounded up.
- Proportionate adjustment to exercise prices and share counts of options/warrants/convertibles.
- Action taken to meet Nasdaq minimum $1.00 bid price continued listing requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024096025/0001213900-24-096025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024096025/ea0220578-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-096025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer